EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Kyverna Therapeutics, Inc. (KYTX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Kyverna Therapeutics, Inc. $3.04, price $7.07, upside -57.0%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US5019761049

KT Kyverna Therapeutics, Inc. logo Thin data Sep 24, 2026

Kyverna Therapeutics, Inc.

KYTX · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $3.04 · Strongly overvalued (−57%)
!Quality 16/100
!Mixed Growth (revenue YoY +24.2 %/yr)
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 5/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
Watch Kyverna Therapeutics, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$30.10 $1.83 Fair Value $3.04 Feb 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

31‑month range $1.83 – $30.10 · fair‑value band $2.01 – $3.81 · the $7.07 price screens above the $3.04 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Kyverna Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Kyverna Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Show more

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Stock analysis

Kyverna Therapeutics, Inc. Common Stock (KYTX) currently trades at $7.07, while our model-based Fair Value estimate is $3.04, implying the stock looks roughly 132.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $2.01 (bear) to $3.81 (bull), the price of $7.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kyverna Therapeutics, Inc. Common Stock reported revenue of $0 in FY2025 versus $5.7M in FY2021. Reported net income was −$161M in FY2025.

Key figures

Market cap $431M · EPS (TTM) $−2.89 · Return on equity −87.2% · Return on assets (EBIT) −52.5% · Free cash flow −$154M · Net cash $95.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −57%, KYTX screens richer than that median.

Fair Value models

Bear $2.01 Fair Value $3.04 Bull $3.81
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.88 $2.52 $3.76 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.88 $2.52 $3.76 51

Open the full fair value analysis →

Notify me when KYTX reaches fair value

Put KYTX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 16/100

Of which business quality 25 · Market factors (momentum, volatility) 26

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 30
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

KYTX screens 132% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Kyverna Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −57% · Below median
Profitability
Return on assets −45% · Bottom 25%
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.85× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kyverna Therapeutics, Inc. Common Stock · Fair Value
$3.04 −132%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Kyverna Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/KYTX

Frequently asked questions

Is Kyverna Therapeutics, Inc. (KYTX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.04 versus a price of $7.07, about −57% upside (overvalued).
What is the fair value of KYTX?
Our model-based fair value for Kyverna Therapeutics, Inc. Common Stock is $3.04 (as of Sep 24, 2026), built from audited fundamentals. The current price: $7.07.
What is the quality score of KYTX?
Kyverna Therapeutics, Inc. Common Stock has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kyverna Therapeutics, Inc. (KYTX)?
Our model-based price target is the fair value of $3.04 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $2.01, optimistic scenario $3.81. It is a calculation from audited fundamentals, not an analyst target.
What is the Kyverna Therapeutics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $3.04, about −57% upside versus a price of $7.07 (overvalued). Cautious scenario $2.01, optimistic scenario $3.81. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Kyverna Therapeutics, Inc. (KYTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kyverna Therapeutics, Inc. Common Stock it is $3.04 per share (as of Sep 24, 2026), against a price of $7.07. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Kyverna Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 24, 2026, KYTX trades above its calculated fair value: price $7.07, fair value $3.04, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KYTX?
No. The price is what the market pays today ($7.07); the fair value is what the company's own numbers justify ($3.04). For Kyverna Therapeutics, Inc. Common Stock the two are $4.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kyverna Therapeutics, Inc. Common Stock worth?
The market values Kyverna Therapeutics, Inc. Common Stock at about $431M (market capitalisation, as of Sep 24, 2026). Per share that is $7.07; our models calculate a fair value of $3.04 per share.
What do the bullish and bearish scenarios say about KYTX?
Our models span a range for Kyverna Therapeutics, Inc. Common Stock: cautious scenario $2.01, base $3.04, optimistic $3.81 per share (as of Sep 24, 2026, price $7.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kyverna Therapeutics, Inc. (KYTX)?
Balance-sheet figures for Kyverna Therapeutics, Inc. Common Stock (as of Sep 24, 2026): return on equity −87.2%. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is KYTX from its 52-week high?
Kyverna Therapeutics, Inc. Common Stock trades at $7.07, about 37% below its 52-week high of $11.25 and 31% above the low of $5.41 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $3.04 is for.
Which stocks are comparable to Kyverna Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kyverna Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Sep 24, 2026: price $7.07, calculated fair value $3.04 (−57%), Quality Score 16/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KYTX calculated?
We run Kyverna Therapeutics, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.04, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Kyverna Therapeutics, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kyverna Therapeutics, Inc. (KYTX)?
The closing price on Sep 23, 2026 was $7.07. Our model-based fair value is $3.04, about −57% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kyverna Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($3.81). The favourable scenario is already priced in. Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.01 to $3.81) leaves room in how you read the outcome.

Key figures of Kyverna Therapeutics, Inc. Common Stock

How large is the market capitalisation of Kyverna Therapeutics, Inc. (KYTX)?
The market capitalisation of Kyverna Therapeutics, Inc. Common Stock is $431M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Kyverna Therapeutics, Inc. (KYTX)?
Earnings per share at Kyverna Therapeutics, Inc. Common Stock are $−2.89. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kyverna Therapeutics, Inc. (KYTX)?
The return on equity (ROE) of Kyverna Therapeutics, Inc. Common Stock is −87.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kyverna Therapeutics, Inc. (KYTX)?
On an EBIT basis the return on assets of Kyverna Therapeutics, Inc. Common Stock is −52.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Kyverna Therapeutics, Inc. (KYTX) generate?
The free cash flow of Kyverna Therapeutics, Inc. Common Stock is −$154M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kyverna Therapeutics, Inc. (KYTX) hold?
Kyverna Therapeutics, Inc. Common Stock holds more cash than debt, $95.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kyverna Therapeutics, Inc. Common Stock in the live analysis

One click puts Kyverna Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.